Oscotec Highlights Scalability of ACART and Anti-Drug Resistance Anticancer Pipeline at R&D Day

Oscotec announced on July 9 that it held the "Oscotec 2026 R&D Day" at the KOSDAQ Association in Yeouido, Seoul, on the afternoon of July 8, where it released the current status of its research and development pipeline, including the anti-drug resistance anticancer agent OCT-598, the ACART platform, and the kidney fibrosis inhibitor project OCT-648.

Oscotec 2026 R&D Day, Oscotec

This event, which has been held annually since 2021, is designed to communicate with the capital market and share the company's R&D status and mid-to-long-term direction. Numerous domestic and international pharmaceutical and biotech analysts, as well as institutional investors, attended the event.

Oscotec particularly focused on explaining the direction of its anti-drug resistance anticancer agent platform ACART, which was initiated in earnest with the establishment of a base technology team in its research institute in May. The ACART platform begins by tracking in real time the process by which cancer cells acquire resistance to existing anticancer drugs, and uses artificial intelligence (AI) to conduct single-cell level image analysis. Oscotec plans to expand this to AI- and systems biology-based analysis to identify the mechanisms behind cancer cell resistance and discover key targets involved in resistance formation.

Oscotec aims to strengthen its R&D capabilities in the field of anti-drug resistance anticancer agents by investing in ACART platform infrastructure, enhancing professional personnel, and expanding partnerships and collaborative research initiatives.

In addition, OCT-598, a technology introduced from Kanaph Therapeutics in 2022, is a dual EP2/EP4 inhibitor and the first-in-class candidate substance being developed to overcome resistance and immune evasion that occur during cancer treatment. Phase 1a clinical trials are underway in Korea, and Phase 1b clinical trials are being prepared in both Korea and the United States.

The kidney fibrosis inhibitor project, OCT-648, is a highly selective NUAK1 inhibitor, and Oscotec plans to make the final selection of a candidate substance in the second half of this year.

CEO Yoon Taeyoung stated, "In the past six months, three contracts—ADEL-Y01, Denpivontinib, and Seviodoplenib—have been signed, reinforcing a virtuous cycle in R&D. The inflow of funds has also laid the groundwork for investing in the ACART platform." He added, "Anti-drug resistance anticancer agents represent a new field of drug development to overcome resistance and immune evasion that occur during existing cancer treatments. Through the ACART platform, we aim to identify differentiated targets and candidate substances, with the goal of achieving at least two technology transfer outcomes by 2030."

Oscotec plans to release a video of the main announcements from this R&D Day on the company website.

This content was produced with the assistance of AI translation services.